Labopharm seeking FDA dispute resolution

Share this content:
Labopharm says it is seeking formal FDA dispute resolution proceedings to counter an approvable letter from the agency requiring undisclosed additional work on its NDA for a once-daily formulation of the pain-reliever tramadol.

Share this content:
Scroll down to see the next article